KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Equity Average (2018 - 2025)

Historic Equity Average for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $871.8 million.

  • Vir Biotechnology's Equity Average fell 3480.51% to $871.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $871.8 million, marking a year-over-year decrease of 3480.51%. This contributed to the annual value of $1.4 billion for FY2024, which is 2528.7% down from last year.
  • According to the latest figures from Q3 2025, Vir Biotechnology's Equity Average is $871.8 million, which was down 3480.51% from $995.6 million recorded in Q2 2025.
  • Vir Biotechnology's Equity Average's 5-year high stood at $2.1 billion during Q4 2022, with a 5-year trough of $683.9 million in Q1 2021.
  • Its 5-year average for Equity Average is $1.4 billion, with a median of $1.5 billion in 2024.
  • Per our database at Business Quant, Vir Biotechnology's Equity Average soared by 18474.35% in 2022 and then crashed by 3480.51% in 2025.
  • Vir Biotechnology's Equity Average (Quarter) stood at $1.2 billion in 2021, then soared by 83.17% to $2.1 billion in 2022, then fell by 22.77% to $1.6 billion in 2023, then dropped by 26.77% to $1.2 billion in 2024, then dropped by 27.08% to $871.8 million in 2025.
  • Its last three reported values are $871.8 million in Q3 2025, $995.6 million for Q2 2025, and $1.1 billion during Q1 2025.